Key details
The first transplant: In October 1988, a young boy in Paris received the world’s first cord blood transplant, using stem cells from his baby sister’s cord blood [1, 2, 3].
How far it has come: More than 40,000 cord blood transplants have since been carried out, and cord blood stem cells are a standard treatment for around 80 life-threatening diseases [2, 4, 5].
Where it’s going next: Research is moving into new areas, from wound healing with umbilical cord stem cells, to cerebral palsy [9, 15].
Today is World Cord Blood Day, which is celebrating its tenth year [4]. In under 40 years, cord blood has gone from a single pioneering transplant to being used in more than 40,000 transplants around the world [2].
Where Did It All Begin?
In October 1988, doctors at the Hôpital Saint-Louis in Paris treated a young boy with Fanconi anaemia, an inherited condition in which the bone marrow fails to make enough blood cells [1].
His baby sister’s cord blood had been collected when she was born, frozen, and taken to Paris for his transplant [3]. Once transplanted, her stem cells settled in his bone marrow and began making the healthy blood cells his own marrow couldn’t [1].
It was the first time cord blood had been used in a transplant [2, 3].
How Far Has Cord Blood Come?
Since then, more than 40,000 cord blood transplants have been carried out worldwide, in children and adults. Around 800,000 cord blood units are stored in public banks, and more than 4 million in family banks [2].
Cord blood stem cells are a standard treatment for around 80 life-threatening diseases [4, 5], including:
- Blood cancers. Leukaemia and lymphoma [4, 5].
- Inherited blood disorders. Thalassaemia and sickle cell disease [5, 6].
- Immune disorders. Severe combined immunodeficiency (SCID) [4, 5].
- Metabolic disorders. Krabbe disease [5, 7].
For most of these transplants, the use of donor cord blood would be required, such as from a sibling or public bank [2, 6]. In inherited conditions, a child’s own cells carry the same genetic fault, which is why a sibling’s cord blood is so valuable.
For example, in a study of 485 patients with thalassaemia or sickle cell disease, survival six years after a transplant of a sibling’s cord blood was 97% [6].
For some conditions, timing is paramount. Krabbe disease is a rare inherited condition that damages the nerves and is fatal without treatment. In a landmark study, all 11 babies given donor cord blood before symptoms appeared (at 12 to 44 days old) survived, and most developed thinking and language skills in line with their age [7].
Where Is Cord Blood Going Next?
The research into cord blood continues in transplant medicine, but also in regenerative medicine.
Alongside the blood-forming stem cells in cord blood, umbilical cord tissue is a rich source of mesenchymal stem cells (MSCs), which have shown the ability to regulate immune responses and promote tissue repair [8]. In clinical trials, researchers are studying cord blood and cord tissue stem cells in:
- Cerebral palsy. In a randomised, placebo-controlled trial, young children who received a sufficient dose of their own stored cord blood showed greater gains in motor function and brain connectivity [9].
- Crohn’s disease. In a randomised trial of 82 patients, umbilical cord MSCs reduced disease activity significantly more than in the control group over 12 months [10].
- Stroke. In a Phase 1 study, all 10 adults given donor cord blood after an ischaemic stroke had improved on standard stroke scales three months later [11].
- Multiple sclerosis. In a study of 20 people, umbilical cord tissue MSCs were safe, with improvements in disability scores, walking, and quality of life [12].
- Osteoarthritis. In an early study of seven patients, a cord blood-derived stem cell treatment regenerated knee cartilage, with results that held over seven years of follow-up [13].
- Type 1 diabetes. In a randomised, placebo-controlled trial, umbilical cord MSCs helped preserve the body’s own insulin production in adults newly diagnosed with type 1 diabetes [14].
- Wound healing. A 2026 analysis of six randomised trials, involving 380 people with diabetic foot ulcers, found that those given umbilical cord MSCs alongside standard care had better ulcer healing and better blood flow to the foot [15].
We have covered some of this research in more detail, including how a sibling’s cord blood could help a child with cerebral palsy and the first US patient treated in a Phase 3 trial of a cord blood stem cell therapy for knee osteoarthritis.
What Does This Mean For Families?
From one sibling’s cord blood in 1988 to more than 40,000 transplants and a constantly growing body of research and clinical trials, cord blood has come a long way, and its potential is still unfolding [2].
None of it would have been possible without saving stem cells at birth, and we’ve seen that first-hand having released 22 samples for use in approved treatments and clinical trials [16].
By storing cord blood, cord tissue, and placenta, you can help protect your baby’s future health. To learn more about umbilical cord stem cells and how you can preserve them, fill in the form below to request your free welcome pack.
References
- Gluckman, E., Broxmeyer, H. E., Auerbach, A. D., et al. (1989). Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. New England Journal of Medicine, 321(17), 1174–1178. https://doi.org/10.1056/NEJM198910263211707
- Mayani, H., Wagner, J. E., & Broxmeyer, H. E. (2020). Cord blood research, banking, and transplantation: Achievements, challenges, and perspectives. Bone Marrow Transplantation, 55(1), 48–61. https://doi.org/10.1038/s41409-019-0546-9
- Broxmeyer, H. E. (2016). Enhancing the efficacy of engraftment of cord blood for hematopoietic cell transplantation. Transfusion and Apheresis Science, 54(3), 364–372. https://doi.org/10.1016/j.transci.2016.05.013
- Save the Cord Foundation. (2026). World Cord Blood Day 2026. https://www.worldcordbloodday.org/
- Parent’s Guide to Cord Blood Foundation. (n.d.). Diseases that can be treated with cord blood. https://parentsguidecordblood.org/en/diseases
- Locatelli, F., Kabbara, N., Ruggeri, A., et al. (2013). Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood, 122(6), 1072–1078. https://doi.org/10.1182/blood-2013-03-489112
- Escolar, M. L., Poe, M. D., Provenzale, J. M., et al. (2005). Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease. New England Journal of Medicine, 352(20), 2069–2081. https://doi.org/10.1056/NEJMoa042604
- Nagamura-Inoue, T., & He, H. (2014). Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World Journal of Stem Cells, 6(2), 195–202. https://doi.org/10.4252/wjsc.v6.i2.195
- Sun, J. M., Song, A. W., Case, L. E., et al. (2017). Effect of autologous cord blood infusion on motor function and brain connectivity in young children with cerebral palsy: A randomized, placebo-controlled trial. Stem Cells Translational Medicine, 6(12), 2071–2078. https://doi.org/10.1002/sctm.17-0102
- Zhang, J., Lv, S., Liu, X., Song, B., & Shi, L. (2018). Umbilical cord mesenchymal stem cell treatment for Crohn’s disease: A randomized controlled clinical trial. Gut and Liver, 12(1), 73–78. https://doi.org/10.5009/gnl17035
- Laskowitz, D. T., Bennett, E. R., Durham, R. J., et al. (2018). Allogeneic umbilical cord blood infusion for adults with ischemic stroke: Clinical outcomes from a phase I safety study. Stem Cells Translational Medicine, 7(7), 521–529. https://doi.org/10.1002/sctm.18-0008
- Riordan, N. H., Morales, I., Fernández, G., et al. (2018). Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. Journal of Translational Medicine, 16(1), 57. https://doi.org/10.1186/s12967-018-1433-7
- Park, Y. B., Ha, C. W., Lee, C. H., Yoon, Y. C., & Park, Y. G. (2017). Cartilage regeneration in osteoarthritic patients by a composite of allogeneic umbilical cord blood-derived mesenchymal stem cells and hyaluronate hydrogel: Results from a clinical trial for safety and proof-of-concept with 7 years of extended follow-up. Stem Cells Translational Medicine, 6(2), 613–621. https://doi.org/10.5966/sctm.2016-0157
- Carlsson, P. O., Espes, D., Sisay, S., Davies, L. C., Smith, C. I. E., & Svahn, M. G. (2023). Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: A Phase I/II randomised double-blind placebo-controlled trial. Diabetologia, 66(8), 1431–1441. https://doi.org/10.1007/s00125-023-05934-3
- Zhang, H., Gu, Y., Zhang, K., & Ouyang, C. (2026). Safety and efficacy of umbilical cord mesenchymal stem cell therapy for diabetic foot ulcers and peripheral artery disease: A systematic review and meta-analysis of randomized controlled trials. The International Journal of Lower Extremity Wounds. https://doi.org/10.1177/15347346261426552
- Cells4Life. (2026). Cells4Life’s cord blood releases. https://cells4life.com/cells4life-difference/cells4lifes-cord-blood-releases/
FIND OUT MORE, REQUEST YOUR WELCOME PACK TODAY
Everything you need to decide about cord blood banking – and, while you decide, Antenatal by Cells4Life: 18 online classes with Cass McNamara, BBC Scotland’s Ask the Midwife, on birth, feeding, newborn care and recovery. It’s free when you request your welcome pack.
Provide your contact details to request:
- Complete Welcome Pack and Parent’s Guide
- Your discount
- save up to £500
on cord blood banking
- Information via email
- Free access to our full 18-class online antenatal course, including a video class on cord blood banking
- A call from one of our specialist advisers


